Research on GLP-1 receptor drugs across the stages from fatty liver disease to liver inflammation and liver cancer

Metabolic dysfunction is linked to hepatocellular carcinoma (HCC) through obesity, type 2 diabetes, and insulin resistance.

• Metabolic dysfunction may contribute to the progression of liver diseases, including steatohepatitis, fibrosis, and cirrhosis, leading to HCC.
• There is a connection between metabolic dysfunction-associated steatotic liver disease (MASLD) and the development of HCC.
• GLP-1 receptor agonists (GLP-1RAs) could potentially address several metabolic factors that influence the MASLD-HCC continuum.
• The relationship between GLP-1RAs and the progression from MASLD to HCC is currently not well understood.

Simplified